
EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS
The European Commission has granted marketing authorization to Rytelo (imetelstat) monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndromes (MDS), according to a …